N-Zyme Biomedical has identified a novel, causal mechanism of disease in reflux (LPR/GERD), owns the mechanism with its IP portfolio, and is rapidly developing clinical-stage assets. With near-term Phase II readout, we are looking to explore strategic partnerships to bring this treatment to the millions of worldwide sufferers of reflux diseases.

• Phase II readout Q4 26/Q1 27
• Novel, validated mechanism of action target for LPR and GERD, where existing treatments don't treat underlying mechanism of disease
• Highly de-risked human safety and efficacy with oral and inhaled modalities
• Rapid and cost-effective clinical trial path; 4x oversubscribed Phase II
• Fully own new mechanism of action in reflux with patent families